Changing the Game on Treating Parvovirus
Summary: Join us for a discussion on Elanco’s new conditionally licensed Canine Parvovirus Monoclonal Antibody. We will present an overview of the current disease state of canine parvovirus, vaccination strategies for success prevention, current treatment options and their challenges, as well as the new therapeutic technology for treatment.